Navigation Links
Hyperparathyroidism in Biological Technology

Cytochroma and Mitsubishi Tanabe form partnership for chronic kidney disease therapies in U.S. and Asia

... an important validation of our novel approach to treating secondary hyperparathyroidism in CKD patients." MTPC's President and Representative Director, Natsuki ... in countries worldwide. About Secondary Hyperparathyroidism Secondary hyperparathyroidism ("SHPT") is a condition commonly associated with chronic kidney disease ...

Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease

... these patients have vitamin D insufficiency, which can lead to secondary hyperparathyroidism and resultant debilitating bone diseases. There is growing evidence that ... portfolio of new therapies for Vitamin D insufficiency and secondary hyperparathyroidism associated with CKD. In addition, the Company is developing novel ...

Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients

... require dialysis. Phosphate retention and the resulting hyperphosphatemia in patients with ESRD on dialysis are usually associated with secondary hyperparathyroidism (and its related cardiovascular complications), renal osteodystrophy and soft tissue mineralization. ESRD patients usually require treatment with ...

Cytochroma Closes $45 Million Series C Financing

... related to altered vitamin D metabolism in chronic kidney disease ("CKD") patients, and include CTA018 and CTAP201 for the treatment of secondary hyperparathyroidism ("SHPT"), and CTAP101 for the treatment of vitamin D insufficiency. These three lead products address significant markets that are expected to grow ...

Fontus Pharmaceuticals Acquires Nephrology and Endocrinology Drug from Roche Laboratories Inc.

... has acquired ROCALTROL(R) (calcitriol) from Roche Laboratories Inc. ROCALTROL is a vitamin D analog prescribed by nephrologists for the management of hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (CRF) and by endocrinologists for the management of ...

Cytochroma Appoints R. Richard Wieland II As CFO

... has three lead product candidates in development for CKD patients: CTA018 and CTAP201 are being developed for the treatment of secondary hyperparathyroidism (SHPT), while CTAP101 is being developed for the treatment of Vitamin D insufficiency. About Chronic Kidney Disease According to the National ...

Cytochroma opens U.S. headquarters in Illinois

... has three lead product candidates in development for CKD patients: CTA018 and CTAP201 are being developed for the treatment of secondary hyperparathyroidism (SHPT), while CTAP101 is being developed for the treatment of Vitamin D insufficiency. About Chronic Kidney Disease According to the National ...

Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO

... for vitamin D deficiency and secondary hyperparathyroidism in patients with moderate-to-severe CKD. ... hyperparathyroidism. If untreated, secondary hyperparathyroidism can cause debilitating bone diseases and ... and preventing vitamin D deficiency and secondary hyperparathyroidism in CKD patients, but Dr. Geoffrey A. Block, ...

Bone Care Names New Chairman

... commercializing improved vitamin D-hormone therapies to treat secondary hyperparathyroidism in patients with kidney (renal) disease, osteoporosis and psoriasis. The ... Injection and Hectorol(R) Capsules for the treatment of secondary hyperparathyroidism in patients with end-stage renal ....

Americas Third Coast nurtures biotechnology

... ) specializes in novel vitamin D therapies for people with chronic kidney disease (CKD). The companys main drug, Hectorol, treats secondary hyperparathyroidism (SHPT) in patients with CKD. Healthy kidneys produce D hormone, which regulates calcium balance. Left untreated, low D hormone levels often ...

FDA approves Bone Cares Hectorol for treatment of kidney disease

... and strength for Hectorol (doxercalciferol) Capsules. Hectorol, a pro-hormone vitamin D2 analog, is currently approved for the treatment of secondary hyperparathyroidism (SHPT) in dialysis patients in the United States, and is now approved for the treatment of SHPT that develops in the earlier stages (stages three and ...

Massachusetts firm to buy UW spinoff Bone Care for $600 million

... chief motive for the merger was to bring Bone Care's flagship product, Hectorol, into its stable of renal disease drugs. Hectorol treats secondary hyperparathyroidism in patients with chronic kidney disease. While Genzyme's Renagel product has gained substantially in the market sales were up 19 percent in the ...

Bone Care expands patent protection of core drug offering

... that will extend protection of its core druc, Hectorol. The patent, which will expire in 2021, covers the company's hormone therapy treatment for hyperparathyroidism in chronic kidney disease patients, as well as the new version of Hectorol which Bone Care is currently working to complete. Bone Care uses ...

FTC has fast-tracked Bone Care merger

... Bone Cares current commercial and therapeutic focus is in nephrology, utilizing Hectorol, a novel vitamin D hormone therapy, to treat secondary hyperparathyroidism in patients with moderate to severe chronic kidney disease and end-stage renal disease. In addition to chronic kidney disease, the company is ...

Genzyme acquistion of Bone Care approved, significant impact forecast

... was based around the research of Hector DeLuca - currently president and CEO of Deltanoid Pharmaceuticals - and is used to treat secondary hyperparathyroidism in patients on dialysis and early stages of chronic kidney disease. Hectorol will be added to Genzyme's renal line of products for treating ...

Genzyme sues former Bone Care employees

... BCI, a company that specialized in Vitamin D products, was best known for producing Hectorol, a Vitamin D drug used to treat secondary hyperparathyroidism in patients on dialysis and in the early stages of chronic kidney disease. As part of a merger, Genzyme purchased BCI last July for an estimated ...
Other Contents
(Date:7/23/2014)... around the world by 2050, according to one of ... Change (IPCC), may be advantageous to the physiology and ... of forage plants such as Stylosanthes capitata Vogel ... countries such as Brazil., The conclusion is from a ... Biology at the Ribeiro Preto Faculty of Philosophy, Sciences ...
(Date:7/23/2014)... MA -- What do mollusks, starfish, and corals ... habitat, they are all calcifiersorganisms that use calcium ... and shells for stability and protection. , The ... published by the Marine Biological Laboratory, addresses the ... changes worldwide. , As atmospheric carbon dioxide rises, ...
(Date:7/23/2014)... 23, 2014   MedNet Solutions , a ... study management systems, is pleased to announce that ... sciences industry executive with over 25 years of ... Clareece will be responsible for MedNet,s day-to-day operating ... and quality product/service delivery.  "We ...
Breaking Biology News(10 mins):An increase in temperature by 2050 may be advantageous to the growth of forage plants 2An increase in temperature by 2050 may be advantageous to the growth of forage plants 3An increase in temperature by 2050 may be advantageous to the growth of forage plants 4Calcification in changing oceans explored in special issue of The Biological Bulletin 2MedNet Appoints Clareece West As Chief Operating Officer 2
(Date:7/23/2014)... the University of Exeter has developed a simple, ... frequently fatal lung disease which attacks immune deficient ... transplant recipients. , The lateral-flow device (LFD), created ... a notoriously difficult to diagnose disease caused by ... , Invasive aspergillosis is a leading cause of ...
(Date:7/23/2014)... Randy Dotinga HealthDay Reporter ... A powerful drug combo may not be as effective ... on human cells suggests that one of the medications ... this study,s findings aren,t definitive, and there,s still hope ... and lumacaftor, according to the study,s senior author. ...
(Date:7/23/2014)... 23, 2014 Home Care Assistance ... for seniors, is proud to announce the next installment ... in a wide range of health and wellness-related fields. ... and award-winning author Nancy Kriseman, and will cover the ... prevent burnout by becoming more self-aware. In particular, Nancy ...
(Date:7/23/2014)... in Shaanxi province, and the University of California, Davis, ... groundwork for establishing the Sino-U.S. Joint Research Center for ... held in the city of Yingchuan, China, during a ... Agriculture and China,s Ministry of Science and Technology. , ... and for our World Food Center and serves as ...
(Date:7/23/2014)... Thousands of DePuy Pinnacle hip lawsuits ... federal multidistrict litigation underway in U.S. District Court, Northern ... an Order dated July 18th, U.S. District Judge Ed ... a $1,000 fee for the preservation and return of ... things, the Order noted that there is no evidence ...
Breaking Medicine News(10 mins):Health News:New device detects deadly lung disease 2Health News:Cystic Fibrosis Drug Combo May Be Less Effective Than Hoped 2Health News:Cystic Fibrosis Drug Combo May Be Less Effective Than Hoped 3Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 2Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 3Health News:Global food safety research agreement signed by China and UC Davis 2Health News:Global food safety research agreement signed by China and UC Davis 3Health News:DePuy Pinnacle Hip Lawsuits Move Forward, as Federal Judge Denies Hospital Bid for $1000 Explant Fee, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Hip Lawsuits Move Forward, as Federal Judge Denies Hospital Bid for $1000 Explant Fee, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Hip Lawsuits Move Forward, as Federal Judge Denies Hospital Bid for $1000 Explant Fee, Bernstein Liebhard LLP Reports 4
Other TagsOther Tags